Personalized Medicine and Imaging Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)

Purpose: Not all breast cancers respond to lapatinib. A change in Ki67 after short-term exposure may elucidate a biomarker profile for responsive versus nonresponsive tumors. ExperimentalDesign:Womenwith primary breast cancerwere randomized (3:1) to 10 to 14 days of preoperative lapatinib or placebo in a multicenter phase II trial (ISRCTN68509377). Biopsies pre-/posttreatment were analyzed for Ki67, apoptosis, HER2, EGFR, ER, PgR, pAKT, pERK, and stathmin by IHC. Further markers weremeasured by RT-PCR. Primary endpoint was change in Ki67. HER2þ was defined as 2þ/3þ by IHC and FISHþ. Results: One hundred twenty-one patients (lapatinib, 94; placebo, 27) were randomized; of these, 21% were HER2þ, 78% were HER2 nonamplified, 26% were EGFRþ. Paired samples containing tumor were obtained for 98% (118 of 121). Ki67 fell significantly with lapatinib ( 31%; P < 0.001), but not with placebo ( 3%). Whereas Ki67 reduction with lapatinib was greatest in HER2þ breast cancer ( 46%; P 1⁄4 0.003), there was a significant Ki67 decrease in HER2 breast cancer ( 27%; P 1⁄4 0.017) with 14% of HER2 breast cancer demonstrating 50% Ki67 reduction with lapatinib. Among HER2þ patients, the only biomarker predictive of Ki67 response was the EGFR/HER4 ligand epiregulin (EREG) (rho 1⁄4 0.7; P 1⁄4 0.002). Among HER2 tumors, only HER3 mRNA levels were significantly associated with Ki67 response on multivariate analysis (P 1⁄4 0.01). In HER2 breast cancer, HER2 and HER3 mRNA levels were highly correlated (rho 1⁄4 0.67, P < 0.001), with all Ki67 responders having elevated HER3 and HER2 expression. Conclusions: Lapatinib has antiproliferative effects in a subgroup of HER2 nonamplified tumors characterized by high HER3 expression. The possible role of high HER2:HER3 heterodimers in predicting response to lapatinib merits investigation in HER2 tumors. Clin Cancer Res; 21(13); 2932–40. 2014 AACR. See related commentary by Campbell and Moasser, p. 2886